A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Non-hodgkin's Lymphoma

Interventions

DRUG

GNC-038

Administration by intravenous infusion

Trial Locations (3)

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Harbin First Hospital, Haerbin

RECRUITING

Qingdao Central Hospital, Qingdao

All Listed Sponsors

collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05623982 - A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter